Senate Bill 51

Actions | Amendments
Last Action 04/08/21: signed by Governor (Acts Ch. 201)
Title AN ACT relating to addiction treatment.
Bill Documents Current/Final
Introduced
Fiscal Impact Statements Health Mandate
Additional Fiscal Impact Statements Exist
Bill Request Number 1017
Sponsor R. Alvarado
Summary of Original Version Amend KRS 304.17A-611 to prohibit insurers from requiring or using certain utilization reviews for certain prescription drugs used to treat alcohol or opioid use disorder; amend KRS 205.536 to prohibit the Department for Medicaid Services or a Medicaid managed care organization from requiring or using certain utilization reviews for certain prescription drugs used to treat alcohol or opioid use disorder; create a new section of Subtitle 17A of KRS Chapter 304 to require insurers to report the number and type of providers prescribing medication for addiction treatment; require the Department of Insurance to report to the General Assembly and State Board of Medical Licensure; EFFECTIVE in part January 1, 2022.
Index Headings of Original Version Health Benefit Mandate - Treatment of opiod or alcohol use disorder, utilization reviews, prohibition
Drugs and Medicines - Treatment of opioid or alcohol use disorder, utilization reviews, prohibition
Effective Dates, Delayed - Treatment of opioid or alcohol use disorder, utilization reviews, prohibition, January 1, 2022
Insurance, Health - Insurers, report, medication for addiction treatment
Insurance, Health - Treatment of opioid or alcohol use disorder, utilization reviews, prohibition
Public Medical Assistance - Medicaid coverage, utilization review, prohibition
State Agencies - Department for Medicaid Services, utilization review, prohibition
State Agencies - Department of Insurance, medication for addiction treatment, report
Medicaid - Department for Medicaid Services, utilization review, prohibition
Alcoholism - Treatment of opioid or alcohol use disorder, utilization reviews, prohibition
Reports Mandated - Department of Insurance, prescriptions for addiction treatment
Jump to Proposed Amendments Senate Committee Substitute 1 with Fiscal Impact Statements
House Floor Amendment 1
Votes Vote History

Actions

Top | Amendments
01/05/21
  • introduced in Senate
  • to Committee on Committees (S)
01/11/21
  • to Health & Welfare (S)
02/10/21
  • reported favorably, 1st reading, to Calendar with Committee Substitute (1)
02/11/21
  • 2nd reading, to Rules
02/22/21
  • posted for passage in the Regular Orders of the Day for Tuesday, February 23, 2021
02/23/21
  • 3rd reading, passed 34-0 with Committee Substitute (1)
02/24/21
  • received in House
02/25/21
  • to Health & Family Services (H)
03/01/21
  • posted in committee
03/04/21
  • reported favorably, 1st reading, to Calendar
03/05/21
  • 2nd reading, to Rules
03/12/21
  • posted for passage in the Regular Orders of the Day for Monday, March 15, 2021
03/29/21
  • floor amendment (1) filed
03/30/21
  • 3rd reading, passed 87-2 with floor amendment (1)
  • received in Senate
  • to Rules (S)
  • posted for passage for concurrence in House floor amendment (1)
  • Senate concurred in House floor amendment (1)
  • Bill passed 36-0
  • enrolled, signed by President of the Senate
  • enrolled, signed by Speaker of the House
  • delivered to Governor
04/08/21
  • signed by Governor (Acts Ch. 201)

Proposed Amendments

Top | Actions
Amendment Senate Committee Substitute 1
Fiscal Impact Statement Health Mandate to Senate Committee Substitute 1
Summary Retain original provisions; except amend KRS 304.17A-611 and KRS 205.536 to prohibit concurrent and prospective utilization review of prescription drugs that are FDA-approved for the mitigation of opioid withdrawal; require the Department of Insurance to report to the Kentucky Board of Nursing; create a new section of KRS Chapter 222 to require a treating facility to submit a written discharge plan to the patient and the patient's third-party payor.
Index Headings Insurance, Health - Prescription drugs, mitigation of withdrawal symptoms, utilization review, prohibition
Physicians and Practitioners - Medication for addiction treatment, discharge plan, required
State Agencies - Department of Insurance, prescriptions for addiction treatment
Medicaid - Prescription drugs, mitigation of withdrawal symptoms, utilization review, prohibition
Reports Mandated - Department of Insurance, prescriptions for addiction treatment
Opioids - Prescription drugs, mitigation of withdrawal symptoms, utilization review, prohibition
Health Benefit Mandate - Prescription drugs, mitigation of withdrawal symptoms, utilization review, prohibition

Amendment House Floor Amendment 1
Sponsor K. Moser
Summary Retain original provisions except amend Section 2 to insert conforming language; amend Sections 1 and 2 to limit requirements for prescription drugs approved for the mitigation of opioid withdrawal symptoms; and require the Cabinet for Health and Family Services or the Department for Medicaid Services to apply for a waiver or authorization and report to the co-chairs and Interim Joint Committee on Health, Welfare, and Family services if certain conditions are met.
Index Headings Drugs and Medicines - Addiction treatment, utilization review, prohibition
Insurance, Health - Prescription drugs, mitigation of opioid withdrawal symptoms, utilization review, prohibition
Medicaid - Prescription drugs, medication for addiction treatment, utilization review, prohibition
Opioids - Prescription drugs, mitigation of withdrawal symptoms, utilization review, prohibition
Reports Mandated - Cabinet for Health and Family Services, waiver application, utilization review
State Agencies - Cabinet for Health and Family Services, waiver application, utilization review

Last updated: 4/11/2021 12:15 AM (EDT)
To receive notice when the record is updated follow @LRCTweetBot.